Kristin D Kistler1, Jill Kalman2, Gagan Sahni3, Brian Murphy4, Winifred Werther5, Kanya Rajangam6, Ajai Chari3. 1. Evidera, Waltham, MA. Electronic address: Kristin.kistler@evidera.com. 2. North Shore-Long Island Jewish Health System, Lenox Hill Hospital, New York, NY. 3. Mount Sinai School of Medicine, New York, NY. 4. Evidera, Waltham, MA. 5. Onyx Pharmaceuticals, Inc, an Amgen Subsidiary, South San Francisco, CA. 6. Cleave Biosciences, Inc, Burlingame, CA.
Abstract
BACKGROUND: Multiple myeloma (MM) patients have age-, disease-, and treatment-related risk factors for cardiac events. MATERIALS AND METHODS: We analyzed the 2006 to 2011 MarketScan database to determine whether the risk of cardiac events is greater in MM patients than in non-MM patients. Included were 1723 MM patients treated with corticosteroids and ≥ 3 drugs (bortezomib, immunomodulatory derivatives, and alkylating agents or anthracyclines). The index date (ID) was the date on which the 3-drug exposure criterion was met. Also included were 8615 age- and gender-matched non-MM patients (5:1). The distribution of non-MM patients' IDs matched that of the MM patients' IDs. Baseline was 6 months before the ID. The follow-up duration was from the ID to study end (ie, 2011 or end of enrollment or prescription drug coverage). Hazard ratios (HRs) and 95% confidence intervals (CIs) were adjusted for baseline variables when the univariate analyses showed a 10% difference. RESULTS: The median duration of observation was 9 months (range, 0-60 months) for MM patients and 19 months (range, 0-66 months) for non-MM patients. The risk of any cardiac event (HR, 2.2; 95% CI, 1.9-2.5), dysrhythmia (HR, 4.1; 95% CI, 3.5-4.8), congestive heart failure (HR, 2.9; 95% CI, 2.2-3.7), cardiomyopathy (HR, 2.6; 95% CI, 1.8-3.8), and conduction disorders (HR, 1.7; 95% CI, 1.2-2.5) was significantly greater for MM than for non-MM patients. The incidence of hypertensive or arterial events and ischemic heart disease was similar between the 2 groups. CONCLUSION: The present study provides the first known comparison of cardiac event risk in patients with MM versus age- and gender-matched patients without MM. The cardiac event risk was greater in MM patients with ≥ 3 previous drugs for any cardiac event, dysrhythmias, congestive heart failure, cardiomyopathy, and conduction disorders compared with patients without MM.
BACKGROUND:Multiple myeloma (MM) patients have age-, disease-, and treatment-related risk factors for cardiac events. MATERIALS AND METHODS: We analyzed the 2006 to 2011 MarketScan database to determine whether the risk of cardiac events is greater in MM patients than in non-MM patients. Included were 1723 MM patients treated with corticosteroids and ≥ 3 drugs (bortezomib, immunomodulatory derivatives, and alkylating agents or anthracyclines). The index date (ID) was the date on which the 3-drug exposure criterion was met. Also included were 8615 age- and gender-matched non-MM patients (5:1). The distribution of non-MM patients' IDs matched that of the MM patients' IDs. Baseline was 6 months before the ID. The follow-up duration was from the ID to study end (ie, 2011 or end of enrollment or prescription drug coverage). Hazard ratios (HRs) and 95% confidence intervals (CIs) were adjusted for baseline variables when the univariate analyses showed a 10% difference. RESULTS: The median duration of observation was 9 months (range, 0-60 months) for MM patients and 19 months (range, 0-66 months) for non-MM patients. The risk of any cardiac event (HR, 2.2; 95% CI, 1.9-2.5), dysrhythmia (HR, 4.1; 95% CI, 3.5-4.8), congestive heart failure (HR, 2.9; 95% CI, 2.2-3.7), cardiomyopathy (HR, 2.6; 95% CI, 1.8-3.8), and conduction disorders (HR, 1.7; 95% CI, 1.2-2.5) was significantly greater for MM than for non-MM patients. The incidence of hypertensive or arterial events and ischemic heart disease was similar between the 2 groups. CONCLUSION: The present study provides the first known comparison of cardiac event risk in patients with MM versus age- and gender-matched patients without MM. The cardiac event risk was greater in MM patients with ≥ 3 previous drugs for any cardiac event, dysrhythmias, congestive heart failure, cardiomyopathy, and conduction disorders compared with patients without MM.
Authors: Maximilian Mair; Christian Straka; Thomas Buratti; Martina Tauber; Manfred Mitterer; Dominic Fong Journal: Ann Hematol Date: 2020-03-05 Impact factor: 3.673
Authors: Adam J Waxman; Suparna Clasen; Wei-Ting Hwang; Alfred Garfall; Dan T Vogl; Joseph Carver; Rupal O'Quinn; Adam D Cohen; Edward A Stadtmauer; Bonnie Ky; Brendan M Weiss Journal: JAMA Oncol Date: 2018-03-08 Impact factor: 31.777
Authors: Sara Bringhen; Alberto Milan; Claudio Ferri; Ralph Wäsch; Francesca Gay; Alessandra Larocca; Marco Salvini; Evangelos Terpos; Hartmut Goldschmidt; Michele Cavo; Maria Teresa Petrucci; Heinz Ludwig; Holger W Auner; Jo Caers; Martin Gramatzki; Mario Boccadoro; Hermann Einsele; Pieter Sonneveld; Monika Engelhardt Journal: Haematologica Date: 2018-07-26 Impact factor: 9.941